截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 今海醫療科技股份有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02225 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | 本月底 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 致：香港交易及結算所有限公司 公司名稱: 今海醫療科技股份有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02225 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | 本月 ...

Core Insights - The Chinese medical device industry is undergoing structural changes, shifting from scale expansion to a focus on "innovation-driven," "domestic substitution," and "overseas layout" [1] - Jin Hai Medical, a key player in the minimally invasive surgery sector, exemplifies this industry evolution through its strategic development and innovation [1] Company Development and Achievements - Since its transformation in 2021, Jin Hai Medical has obtained 13 medical device registration certificates in China, demonstrating its robust R&D and quality management systems [3] - The company has made significant breakthroughs in endoscope technology, including the development of a 4K 3D fluorescence endoscope system, positioning it as a leader in high-end medical equipment [3] Strategic Focus and Market Expansion - Jin Hai Medical is diversifying its product offerings into areas such as spinal minimally invasive surgery and is investing in AI technologies for surgical applications [4] - The collaboration with Medtronic aims to develop integrated solutions for spinal endoscopy, enhancing the company's technological capabilities and market reach [6][7] Technological Innovation and Collaboration - The partnership with Medtronic represents a strategic shift from being a technology follower to an ecosystem builder, focusing on the integration of navigation and endoscopy technologies [6][7] - This collaboration is expected to improve surgical precision and safety, addressing the increasing demand for high-quality surgical solutions in China [6][7] Global Market Strategy - Jin Hai Medical is implementing a dual registration strategy, simultaneously pursuing approvals in domestic and international markets, which accelerates its global market entry [10] - The company has successfully penetrated various international markets, including Europe and Southeast Asia, showcasing its product adaptability and competitive edge [10] Service and Training Support - Jin Hai Medical has established a comprehensive clinical empowerment system, providing training and support to healthcare professionals, which enhances product adoption and technical dissemination [11] - This approach not only facilitates product usage but also builds a strong reputation within the industry, giving the company a competitive advantage [11] Market Outlook - The minimally invasive surgical instrument and consumables market in China is projected to grow from 236 billion yuan in 2023 to 407 billion yuan by 2028, with a CAGR of 11.5% [12] - Jin Hai Medical is well-positioned to capitalize on this growth, leveraging its strategic alliances and technological advancements [14]

Core Viewpoint - The Chinese medical device industry is undergoing structural changes, shifting from scale expansion to a focus on "innovation-driven," "domestic substitution," and "overseas layout" as core themes for growth [2] Group 1: Company Development and Achievements - Since its transformation in 2021, the company has obtained 13 medical device registration certificates in China, demonstrating its robust R&D and quality management systems [3] - The company plans to acquire additional registration certificates by the end of this year and aims for two Class III certificates next year, indicating a steady progression in its regulatory achievements [3] - The company has made significant breakthroughs in endoscope technology, including the development of a 4K 3D naked-eye fluorescence endoscope system, positioning itself as a leader in high-end medical equipment [3][4] Group 2: Strategic Focus and Market Positioning - The company is diversifying its product offerings into areas such as spinal minimally invasive surgery and is investing in AI and surgical intelligence, aligning with future medical trends [4] - The collaboration with clinical experts is seen as a perfect match for advancing AI in surgery, particularly in spinal surgery, enhancing the company's market positioning [4][7] - The company has strategically chosen to focus on the under-served market of osteoporosis vertebral fractures, developing a bone cement infusion robot to address specific clinical needs [9] Group 3: Strategic Partnerships and Ecosystem Development - The strategic partnership with Medtronic aims to develop integrated solutions for navigation spinal endoscopy, enhancing the surgical process's visibility and safety [7][8] - This collaboration represents a shift from being a technology follower to an ecosystem builder, allowing the company to access global high-end medical markets and absorb advanced product concepts [8][11] - The company has established a dual registration mechanism for both domestic and international markets, significantly reducing the time from local launch to international expansion [11] Group 4: Market Trends and Future Outlook - The minimally invasive surgical instrument and consumables market in China is projected to reach 236 billion yuan in 2023, with a compound annual growth rate (CAGR) of 11.5% expected from 2023 to 2028 [13] - The company is well-positioned in this growing market due to its solid qualifications, forward-looking technology positioning, and top-tier ecosystem alliances [16] - The company is seen as a "silent warrior" in the market, with its strong entry barriers and clear technological pathways contributing to its value creation [17]

Jinhai Medical Technology Limited 今海醫療科技股份有限公司 （於開曼群島註冊成立的成員有限責任公司） （股份代號：2225） 更改香港主要營業地點 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 承董事會命 今海醫療科技股份有限公司 董事會主席兼執行董事 陳國寶 香港，二零二五年十一月十八日 於本公告日期，董事會由八名董事組成，其中三名執行董事為陳國寶先生、王振飛 先生及李雲平先生；兩名非執行董事為蔣江雨先生及王華生先生；及三名獨立非 執行董事為嚴健軍先生、范一民先生及楊美華女士。 今海醫療科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，自二 零二五年十一月十九日起，本公司香港主要營業地點將更改為「香港灣仔告士打 道178號華懋世紀廣場20樓2002室」。本公司電話及傳真號碼、電郵及網站均維持不 變。 ...

Core Insights - The collaboration between Jin Hai Medical Technology Co., Ltd. and Medtronic Kanghui marks a significant advancement in the field of spinal minimally invasive surgery through the launch of the "navigation-based spinal endoscopic minimally invasive technology" [1][3][4] Group 1: Technology Integration - The newly launched technology integrates Jin Hai Medical's advanced spinal endoscopic system with Medtronic Kanghui's locally developed "Qinghang™ EngineNav™ spinal surgical navigation system," enabling visual guidance and standardized operations throughout the surgical process [3][4] - This integration aims to enhance surgical efficiency and precision while significantly reducing surgical trauma and shortening patient recovery times, addressing the urgent clinical demand for minimally invasive and intelligent surgical solutions [3][4] Group 2: Ecosystem Development - The partnership signifies a shift in China's medical technology landscape from being a "follower" to a "co-creator," showcasing Jin Hai Medical's expertise in spinal endoscopy to enhance Medtronic Kanghui's product offerings and clinical service capabilities [4][8] - This "dual empowerment" approach is expected to break through resource and technology boundaries in the global spinal minimally invasive field, advancing towards a higher dimension of "system services" [4] Group 3: Ongoing Engagement - The collaboration will continue to engage at the COA conference until November 14, featuring multiple academic activities focused on cutting-edge topics such as "visible correction art," "precision breakthroughs in 'life danger zones'," and "comprehensive solutions for spinal minimally invasive endoscopy" [6] - These activities will provide a high-quality platform for communication among experienced experts and clinical doctors regarding the latest applications and values of navigation and endoscopic technologies in complex spinal surgeries [6] Group 4: Future Vision - Jin Hai Medical is committed to fostering innovation within an open and collaborative ecosystem, aiming to accelerate the adoption of "navigation-based spinal endoscopic minimally invasive technology" across China and globally [8] - The company plans to continue its partnership with Medtronic Kanghui and other global partners to ensure that the principles of "more minimally invasive, more intelligent, and more precise" surgeries benefit a larger patient population [8]

Core Insights - The collaboration between Jin Hai Medical (02225.HK) and Medtronic Kanghui marks a significant milestone with the launch of the "Navigation-based Spinal Endoscopy Minimally Invasive Technology" [1] - This technology integrates Jin Hai Medical's spinal endoscopy system with Medtronic Kanghui's "Qinghang™" surgical navigation system, aiming to advance spinal surgery towards a new phase of "visualization, precision, and minimally invasiveness" [1] - The event is part of the "New Thinking, Shared Moments" series, which includes multiple technical sharing sessions to showcase the strategic upgrade from "single-point innovation" to "system service" [1]

Core Viewpoint - The stock of Jianghai Medical Technology (02225.HK) has seen a significant increase, rising over 13% and currently trading at 1.29 HKD with a trading volume of 13.0365 million HKD [2] Company Summary - Jianghai Medical Technology's stock price increased by 5.74% at the time of reporting [2] - The total trading volume reached 13.0365 million HKD, indicating active market participation [2]

Core Viewpoint - Jin Hai Medical Technology (02225) has seen a significant stock increase of over 13%, currently trading at 1.29 HKD with a transaction volume of 13.0365 million HKD, following the announcement of a strategic cooperation framework agreement with Medtronic for the promotion of real-time navigation tracking endoscopic spine technology in China [1] Group 1: Strategic Cooperation - Jin Hai Medical Technology's subsidiary, Jin Hai Shanghai, has entered into a strategic cooperation framework agreement with Medtronic Changzhou to develop a leading domestic and internationally advanced integrated solution for navigation endoscopic spine technology [1] - The agreement aims to address clinical needs and will involve resource investment for domestic and international academic exchange activities to promote the clinical academic exchange and technological advancement of real-time navigation tracking endoscopic spine technology in China [1] - Both parties will provide navigation endoscopic spine prototypes for clinical demonstrations, training, and marketing activities to support the testing and evaluation of the technology [1] Group 2: Upcoming Events - The 8th China International Import Expo (CIIE) will be held in Shanghai from November 5 to 10, during which Jin Hai Medical Technology will jointly launch the latest developed navigation endoscopic spine innovation technology with Medtronic China [1] - This new technology is expected to be applicable in spinal surgery, paving the way for precision and intelligent development in spinal procedures, while also shortening the learning curve for clinicians in endoscopic spine technology [1] - The initiative is anticipated to facilitate more efficient and widespread clinical applications in the future [1]

Core Viewpoint - Jinhai Medical Technology (02225) has seen a significant stock increase of over 13%, currently trading at 1.29 HKD, with a transaction volume of 13.0365 million HKD, following the announcement of a strategic cooperation framework agreement with Medtronic for the promotion of real-time navigation tracking endoscopic spine technology in China [1] Group 1: Strategic Cooperation - Jinhai Medical Technology's subsidiary, Jinhai Shanghai, has entered into a strategic cooperation framework agreement with Medtronic Changzhou to develop a leading domestic and internationally advanced integrated solution for navigation endoscopic spine technology [1] - The partnership aims to address clinical needs, organize domestic and international academic exchange activities, and promote the clinical academic exchange and technological advancement of real-time navigation tracking endoscopic spine technology in China [1] - Both parties will provide navigation endoscopic spine prototypes for clinical demonstrations, training, and marketing activities to support the testing and evaluation of the technology [1] Group 2: Upcoming Events - The 8th China International Import Expo (CIIE) will be held in Shanghai from November 5 to 10, during which Jinhai Medical Technology will jointly launch the latest developed navigation endoscopic spine innovation technology with Medtronic China [1] - This new technology is expected to be applicable in spinal surgery, paving the way for precision and intelligent development in spinal procedures, while also shortening the learning curve for clinicians in endoscopic spine technology [1] - The initiative is anticipated to facilitate more efficient and widespread clinical applications in the future [1]